{
  "docId": "019de075-e1f8-726f-9315-81fdfad7abab",
  "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Spyre Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 37,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 7,
  "notes": "The slide uses a combination of a pharmacokinetic simulation line chart and a bar chart showing clinical remission rates by exposure quartile.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/16",
  "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab",
  "deckJsonHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab.json",
  "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.42,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Gemini I: Week 6 Clinical Remission Rates in UC (%)",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa761d73-e0ef-4f31-8108-34fb8c2e25ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "chart",
      "text": "SPY001 INDUCTION SIMULATION BASED ON 50-DAY HALF-LIFE",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "176228fd-daba-485c-af67-a450a261c677",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.03,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "Source: 1Vedolizumab exposure-response data from Rosario, M., et. al. (2017); Vedolizumab FDA Clinical Pharmacology Review",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40a12e96-c624-4f9d-bdc9-82727030384d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Expected interim PK data will also inform our ability to test induction exposure-response relationship in Phase 2",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7051eda6-25ad-4d93-8324-7dbeae039797",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chartjunk Elimination",
      "slug": "chartjunk-elimination",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "d600b33c-a8d6-49b1-90f7-3a7f92db6e44",
      "evidence": "The slide includes a clear and simple chart/line: SPY001 INDUCTION SIMULATION BASED ON 50-DAY HALF-LIFE",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 19,
      "from": 6,
      "beatId": "68c6fca4-e8f4-4ede-b0dc-880b8c41a146",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents a detailed solution, including SPY001 and SPY002, from pages 6 to 19",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 19,
      "from": 6,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "0f2e25ea-e3dc-4c15-9e23-1d88590fd563",
      "evidence": "The solution section presents a clear 'why' for Spyre's approach",
      "position": 1,
      "objective": "Why does Spyre's approach make sense?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}